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Abstract
The mitochondrial protein Bcs1p is conserved from Saccharomyces cerevisiae to humans and its C-terminal region exhibits an AAA (ATPases associated with diverse cellular activities) domain. The absence of the yeast Bcslp leads to an assembly defect of the iron-sulfur protein (ISP) subunit within the mitochondrial respiratory complex III, whereas human point mutations located all along the protein cause various pathologies. We have performed a structure-function analysis of the yeast Bcslp by randomly generating a collection of respiratory-deficient point mutants. We showed that most mutations are in the C-terminal region of Bcslp and have localized them on a theoretical three-dimensional model based on the structure of several AAA proteins. The mutations can be grouped into classes according to their respiratory competence and their location on the three-dimensional model. We have further characterized five mutants, each substituting an amino acid conserved in yeast and mammalian Bcsl proteins but not in other AAA proteins. The effects on respiratory complex assembly and Bcslp accumulation were analyzed. Intragenic and extragenic compensatory mutations able to restore complex III assembly to the mutants affecting the AAA domain were isolated. Our results bring new insights into the role of specific residues in critical regions that are also conserved in the human Bcslp. We show that (1) residues located at the junction between the Bcs1p-specific and the AAA domains are important for the activity and stability of the protein and (2) the residue F342 is important for interactions with other partners or substrate proteins.
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INTRODUCTION
Bcs1p is required for the biogenesis of the mitochondrial respiratory complex III and this function is conserved from yeast to humans.1-4 In the yeast Saccharomyces cerevisiae, complex III is embedded in the inner membrane and is composed of 10 subunits: the 3 catalytic subunits Cytbp, Cyt1p, and the iron-sulfur protein (ISP) and 7 structural subunits. The structure of complex III has been determined5 and a model for its assembly has been proposed in which subcomplexes would associate to form precomplexes prior to the late incorporation of ISP ' The absence of Bcslp prevents the assembly of the ISP within complex III and leads to a complete respiratory deficiency1,3 Bcslp interacts with complex III in an ATP-dependent manner but no direct interaction with ISP has been reported so far. Moreover, the presence of the iron-sulfur cluster within the ISP is not essential for Bcs1p function. Thus, the mechanism by which Bcs1p controls the incorporation of ISP into complex III remains to be elucidated. Two other factors, Cbp3 and Cbp4, are also required for the assembly of complex III. Their absence leads to a defect in the assembly of several complex III subunits.8-10
In humans, pathogenic mutations have been localized in the different domains of the Bcs1 protein and they lead to various clinical presentations and biochemical defects: complex III deficiency, increase in the production of reactive oxygen species, as well as iron overload.2,4,11-14 Because the yeast and human proteins are orthologs, several mutations leading to various diseases have already been introduced in the yeast gene to rapidly assess the functionality of the proteins by looking at the respiratory growth of the cells. BCS1L knockdown performed in human cells caused the disassembly of the respiratory chain.15 However, several studies suggest that Bcs1 proteins can be involved in other functions besides their role in complex III assembly. For example, mouse Bcs1p is expressed in certain neuronal structures but there is no strict correlation between Bcs1p and ISP expression.16 Finally, in plants, Bcsl is one of the mitochondrial proteins induced by a variety of stress treatments.17-19
Bcsl proteins are anchored in the mitochondrial inner membrane by a transmembrane segment and have an Nout-Cin orientation. They consist of three distinct domains: the N-terminal domain, the Bcs1p-specific domain, and finally, the AAA (ATPases associated with diverse cellular activities) domain at the C-terminus (Fig. 1a). The N-terminal domain presents an internal targeting signal required for the targeting of Bcs1p to mitochondria.20,21 The C-terminal AAA domain is the most conserved amongst the different Bcsl proteins. Members of the AAA family share a 200- to 250-amino-acid domain that binds ATP and exhibits common structural elements and motifs [Walker A, Walker B, and second region of homology (SRH)]. They often form oligomeric complexes that drive ATP-dependent dissociation and unfolding/folding of nucleic acids or proteins (for reviews, see Refs. 22-24). In the mitochondria, AAA proteases that exert a chaperone-like activity and degrade non-assembled membrane proteins have been extensively studied (for a review, see Ref. 25); however, the membrane-bound Bcs1 proteins constitute a different mitochondrial AAA protein subfamily.






In order to further understand the role of the various domains of Bcs1p and their intramolecular interactions, we have undertaken a structure-function analysis in yeast. We have randomly generated a mutant collection with stringent or thermosensitive respiratory deficiencies and located the corresponding mutations on a theoretical structural model of the AAA domain of Bcs1p. Complex III assembly and Bcs1p accumulation were further analyzed in five mutants. We have also isolated and characterized intragenic and extragenic compensatory mutations restoring respiratory competence to the mutants affecting the AAA domain. Comparison of the positions of the mutations and compensatory mutations in yeast with the pathogenic mutations in humans gives new insights into the role of critical residues in the AAA domain.

RESULTS
Generation of a collection of respiratory-deficient mutants in Bcslp
To investigate the function of the different domains of Bcs1p, we used a random PCR-based mutagenesis strategy to introduce mutations in the BCS1 gene cloned in a low-copy plasmid. The respiratory phenotypes of the transformants were tested on glycerol/ethanol medium at 28 and 36 °C; in total, 121 displayed a respiratory growth defect. Plasmids were recovered from 32 transformants representative of the different phenotypic classes. The BCS1 open reading frame and 100 bp downstream and upstream of the gene were sequenced to identify the nature of the mutation (s). Fourteen carried a single amino acid substitution, 12 carried two substitutions, and 6 carried between three and four substitutions (Table 1). Based on their respiratory growth at 28 and 36 °C, they can be classified into three groups: (i) weak growth, e.g., M310V, (ii) thermosensitive growth, e.g., C289Y and F432I, and (iii) no growth, e.g., F342C and E212G (Fig. 2a). Among the 14 mutants carrying a single amino acid substitution, 1 is located in the N-terminal import region and the other 13 are near or in the C-terminal AAA domain, stressing the importance of this domain (Fig. 1a).
At present, no crystal structure of Bcs1p is available, so we have built a theoretical three-dimensional model of the AAA domain of Bcs1p based on 16 existing structures of AAA proteins (for reviews, see Refs. 22 and 26) and localized 11 mutations on this model (Fig. 1b). Based on their positions on the structure, the mutants can be subdivided into three subclasses. Three (Y392H, F412I, and F432I) affect the C-terminal helical subdomain closing the nucleotide-binding site. Seven (G256D, F276S, A279T, C289Y, M310V, T363I, and T363A) are present in the N-terminal Rossman-fold subdomain that binds  the nucleotide and contains  the two highly conserved Walker A and B motifs and the SRH. One (F342C) is located quite far (>20 Å) from the nucleotide-binding site and is not expected to play a direct role in ATP hydrolysis.
Effect of bcs1 mutants on complex III assembly
Five point mutations located either in the three AAA subdomains (F432I, C289Y, and M310V and F342C) or at the junction between the Bcs1-specific and the AAA domains (E212G) were retained for further characterization. Apart from their localization, the choice of the mutants was also dictated by three other criteria: (1) their belonging to different phenotypic classes (Table 1 and Fig. 2a), (2) the position of the mutated residue outside the canonical motifs known to be important for ATP hydrolysis (Walker A and B, SRH) and already well studied by site-directed mutagenesis in various AAA proteins (for a review, see Ref. 27), and (3) the conservation of the residue in the Bcs1 proteins of yeasts and mammals but not in other AAA proteins, suggesting that they might specifically affect Bcs1p function. Only M310V changed a non-conserved residue; this residue appeared to be important as a mutation was also found at this position in the revertant screen (see later).
The assembly of complex III was analyzed in these five mutants by recording cytochrome spectra and determining the steady-state level of the respiratory complex ISP subunit, which is rapidly degraded when the complex is not assembled. A 40% decrease of peaks corresponding to the two cytochromes b and c1 of complex III was observed in the two thermosensitive and two stringent mutants as in Δbcs1 and Δrip1, which lacks ISP (Fig. 2b). In contrast, the cytochrome spectrum of the M310V mutant was identical to that of the wild type. Mitochondrial proteins were purified from the five mutants and analyzed by immunoblotting. The steady-state level of ISP was decreased in M310V and the two thermosensitive mutants, C289Y and F432I, grown at 36 °C, and in F342C, grown at 28 and 36 °C, while the subunit was nearly undetectable in E212G (Fig. 2c). We also investigated whether mutants of the AAA domains showed iron accumulation, since in humans, some patients carrying mutations in the BCS1L gene present iron overload.11,12 We measured the iron content in total cell extracts and purified mitochondria of wild-type and mutant strains grown at the non-permissive temperature. We observed no difference between wild type, Δbcs1, and mutants (data not shown).











Table 1. List of mutants
































N17D, I194T, N297T, D437N	++	+
The single mutants in boldfaced characters are located in the AAA domain. The underlined mutants were further characterized. The mutants were grown on glycerol medium at 28 and 36 °C.

Effect of mutations on Bcs1p accumulation
In order to study the effect of the five mutations on the stability of Bcslp, we have generated an antibody against the soluble domain of the protein. As expected, the antibody revealed a band of about 50 kDa in the wild-type mitochondria that was absent in the Δbcs1 mutant (Fig. 3a). Using this antibody, we observed that the steady-state level of Bcs1p was not affected in M310V and drastically diminished at both temperatures in C289Y but mainly at 36 °C in F432I. In the stringent mutant E212G, Bcs1p accumulation was not modified at 28 °C and decreased at 36 °C. Surprisingly, in the F342C mutant, the anti-Bcs1p antibody revealed a variant protein of higher apparent molecular mass with a total steady-state level twofold higher than that of the wild-type protein. According to Folsch et al., Bcs1p exhibits an Nout-Cin topology and does not contain a classical targeting presequence; moreover, no proteolytic processing of N-terminal was observed when the protein was imported into mitochondria in vitro. However, we wondered whether, in vivo, the aberrant size of the mutated Bcslp could be caused by a defect in maturation at its C- or N-terminus. To address this question, we tagged the C- or N-terminus of the wild-type and mutant Bcs1p with hemagglutinin (HA) epitopes and purified mitochondria from the four constructions. Anti-HA antibody revealed a protein of the expected molecular mass in the C- and N-terminal-tagged wild-type strain, suggesting that there was no maturation of wild-type Bcs1p. With the N-terminal tag, we observed a low accumulation level of the protein in both strains, suggesting that this tag slightly decreased the stability or the import of the protein. As previously observed for the non-tagged Bcs1p, a protein of higher apparent molecular mass was also detected in both the C- and the N-terminal-tagged mutant F342C (Fig. 3a). Taken together, these results indicate that the aberrant size of Bcs1p in the F342C mutant is not caused by a defect in maturation at either the N- or the C-terminus. The mobility shift of the HA-tagged proteins was also observed in total cell extracts showing that this shift is not due to proteolysis of the wild-type protein during the preparation of the mitochondria. Thus, the alteration of the electrophoretic mobility is probably due to an unidentified post-translational modification that could occur at cysteine 342 in the mutant or to a conformational change, preventing the complete unfolding of Bcs1p in SDS buffer.

Fig. 3. Effect of five bcs1 mutations on the protein Bcs1p. (a) Mitochondria were purified from cells grown at 28 and/or 36 °C: CW252 (wt), bcs1::URA3 (Δbcs1), the five point mutants, and the tagged wild-type or F342C strains carrying HA tags at their C-terminus (BCS1-HA and F342C-HA) or N-terminus (HA-BCS1 and HA-F342C) of Bcslp. Mitochondrial proteins were run on SDS-PAGE (10%), immunoblotted, and probed with antibodies against Bcs1p, HA, and Hsp60p as control. Arrows indicate the position of the two forms of Bcs1p observed in wild type or F342C. (b) Mitochondrial proteins were solubilized with digitonin, then analyzed by BN-PAGE and immunoblotted with antibodies against Bcs1p and Cyt1p. The asterisk indicates the position of high molecular mass complexes of 300 and 600 kDa revealed by the anti-Bcs1p. Positions of the supercomplexes III2+IV2 (1) and III2+IV1 (2) and precomplexes III (preIII) are indicated. Protein molecular mass markers are indicated on the left.

Most AAA proteins are active as oligomers, and in humans the Bcsl protein has been detected in high molecular mass complexes.13,14 In order to determine if the yeast Bcslp could also form oligomers, we analyzed wild-type and mutant mitochondria by Blue Native PAGE (BN-PAGE) after solubilization with digitonin to preserve the interactions between complexes (Fig. 3b). As previously shown,28 the anti-Cyt1p antibodies revealed the two supercomplexes III2+IV2 and III2+IV1 in the wild-type strain (>700 kDa) and the precomplexes III in the Δbcs1 mutant resulting from the defect of complex III assembly. In the F342C mutant, the same precomplexes accumulated, but in larger amounts, suggesting that the precomplexes were stabilized in the presence of the mutated form of Bcs1p. The anti-Bcs1p antibodies revealed two high molecular mass complexes of about 300 and 600 kDa in the wild type and the F342C mutant; these complexes were absent in Δbcs1. Thus, the yeast Bcs1p is present in high molecular mass complexes in the wild-type strain and the mutation F342C does not affect the formation of these complexes.
Isolation of intragenic and extragenic compensatory mutations from three mutants of the AAA domain
To identify compensatory mutations, UV mutageneses were performed on Abcsl and on the three point mutants located in the AAA domain that exhibited a clear respiratory phenotype: C289Y, F432I, and F342C. Revertants able to grow on respiratory medium at 28 or 36 °C were selected. No revertant was isolated from Δbcs1, suggesting that no other protein is able to bypass Bcslp, while revertants were obtained from the three point mutants. The BCS1 gene was sequenced in 27 independent revertants (Table 2). Intragenic compensatory mutations associated with the primary mutation were observed in seven revertants from C289Y and eight from F432I. Mitochondral proteins were purified from three of these revertant strains and analyzed by immunoblotting. All exhibited a steady-state level of Bcs1p and ISP similar to that of the wild-type strain (Fig. 4a and b). Thus, these intragenic mutations compensate for the defective mutations by restoring Bcs1p accumulation and allowing insertion of ISP into a functional complex III.











The three mutants were subjected to UV mutagenesis and independent revertants able to grow on respiratory medium at 28 or 36 °C were isolated. For a number of these strains, the BCS1 gene was sequenced. Revertants that were analyzed in Fig. 4 are indicated in bold characters.
From the third mutant, F342C, only extragenic revertants restoring respiratory growth at 28 °C but not at 36 °C were obtained. Genetic crosses between two of these revertants (su1 and su13) showed that the compensatory mutations were located in two different genes. Figure 4b shows that ISP accumulation was partially restored, whereas the variant protein of higher apparent molecular mass still accumulated in the extragenic revertant F342C su1. Thus, there is no direct correlation between the respiratory deficiency and the accumulation of the high molecular mass protein. The fact that several independent extragenic compensatory mutations have been selected from the F342C mutant suggests that the residue at position 342 is involved in interactions with other proteins.
Several compensatory mutations for both thermosensitive mutants affect the residue P226; therefore, we decided to study this residue further. It is located at the junction between the Bcs1p-specific and the AAA domains; in addition, this junction appears to be important, since the mutation E212G exhibits a strong respiratory phenotype. In order to test the phenotype of these compensatory mutations alone, site-directed mutagenesis was performed on position P226 to introduce either a serine or an alanine. No respiratory deficiency was observed, showing that these mutations alone do not interfere with the activity of Bcs1p (Fig. 4c and data not shown). This suggests that the mutations P226A and P226S lead to a gain of function able to compensate for the respiratory deficiency of mutants C289Y or F432I.
This could be due to conformational changes, as proline residues often play important roles in protein tertiary structure and/or dynamics. Interestingly, an analysis of the yeast phosphoproteome29 showed that at least a fraction of Bcs1p is phosphorylated at position serine 227 next to P226. To test the importance of this serine, we have also constructed the S227A mutation, replacing the serine by an alanine that cannot be phosphorylated. The resulting mutant displays a respiratory deficiency that is aggravated at 36 °C (Fig. 4c). Thus, the junction region between the Bcs1p-specific and the AAA domains around P226 controls Bcs1p activity.






In order to investigate the role of the yeast Bcs1 protein domains, we have randomly generated 14 single point mutations and have shown that 13 were located close to or in the AAA domain of the protein. We have studied five mutants representative of the different phenotypic classes and located in different domains of Bcs1p: four are located in three AAA subdomains and one outside. The position of the four mutations and second-site compensatory mutations on the three-dimensional model of the AAA domain allows a better understanding of the intramolecular interactions existing between the various mutated residues and highlights the role of residues that appear critical for Bcslp function. In addition, a comparison of the localization of the yeast mutations with the human pathogenic mutations suggests that these critical regions are conserved through evolution.
The respiratory deficiency of the mutant F432I in the C-terminal nucleotide-binding subdomain can be compensated for by the mutation N388Y, which is located exactly in the hinge region between the N-and C-terminal subdomains. A change at this position might alter the dynamics between the two subdomains, restoring the nucleotide-binding capacity and thus the stability of the mutated Bcslp. In humans, the V353 residue is mutated in a patient with a complex III deficiency (Fig. 5) and is close to the position N388 in yeast. The location of these two amino acids both in yeast and in humans emphasizes a direct role of the hinge region in the activity and stability of Bcslp. The second mutant, C289Y, is located close to the Walker B motif in the N-terminal subdomain, and three compensatory mutations I290M, M310I, and E357G constituting a connected network of amino acids are located in the same region as the primary mutation C289Y. These three compensatory mutations clustered in the N-terminal nucleotide-binding subdomain also restored Bcs1p activity and stability. Interestingly, the mutation M310V has a slight effect on Bcs1p function and stability, and the three residues I290, M310, and E357 are not conserved in humans (e.g., M310 corresponds to A273 in the human protein). Nonetheless, slight structural changes provided by the revertant mutation M310I are probably able to compensate for the drastic effect of mutation C289Y. We have obtained biochemical evidence suggesting that yeast Bcs1p, like the human Bcs1p, is present as oligomers. The size of the 300-kDa high molecular mass complex observed in BN-PAGE might correspond to a homohexamer, a structure frequently observed for AAA proteins (for reviews, see Refs. 23 and 27). It was shown that ATP binding may regulate the assembly of AAA proteins30 (for a review, see Ref. 24). Thus, the barely detectable level of the Bcs1p in both thermosensitive mutants that are close to the nucleotide-binding site could be due to an oligomerisation defect that might trigger Bcs1p degradation.
The pleiotropic compensatory effect of the various P226 substitutions toward the two thermosensitive mutations located in two different AAA subdomains suggests that the restored respiratory phenotype is probably related to an increase in Bcs1p activity rather than to a direct stabilizing effect of the compensatory mutations in position P226. P226 is close to the nucleotide pocket and located at the junction between the AAA and the Bcs1p-specific domains. In other AAA proteins, a glycine, absent in Bcslp, is a key residue of this linker domain that is proposed to propagate nucleotide-dependent changes to other parts of the AAA protein (for a review, see Ref. 27). In the human Bcs1p, two pathogenic mutations, R184C and R183C, are located close to the proline 187 that corresponds to the yeast P226 (Fig. 5). Moreover, it is interesting to note that the mutation of serine 227 that is phosphorylated in the yeast phosphoproteome29 leads to a respiratory defect at 36 °C, a temperature close to that of the human body.

Fig. 5. Comparison of the structural models of the yeast (left) and human (right) AAA domain of Bcs1p. The figure was generated with the Pymol v1.1 software. Important residues are depicted in black space-filling spheres: the three residues modified in the yeast mutants F342, C289, and F342 or in the two compensatory mutations P226 and N388; the four residues modified in human diseases R183, R184, R306, and V353; The ADP nucleotide is represented as dots.


This serine is conserved in humans (S190). Thus, our results demonstrate the importance of this junction region around the residue P226 for Bcslp activity and stability. By comparison with other AAA proteins,31 it is tempting to propose that this junction domain modulates the dynamics between the Bcslp-specific and the AAA domains that probably controls the access of ATP/ADP In our screen, we obtained two mutants with a stringent respiratory deficiency also located near this junction. The characterization of E212G has shown that the assembly of complex III is strongly affected at 28 °C, while the accumulation of Bcslp is not, confirming the importance of this junction for Bcs1p activity. However, as there is no predicted structure for this Bcs1p-specific region, in the future it will be important to determine the crystal structure of these two soluble domains of Bcs1p to further understand the role of this junction region and the effect of mutations.
The mutation F342C is located in a sequence of 15 amino acids (position 340-355) that is highly conserved only in Bcs1 proteins. It presents a stringent respiratory defect associated to the accumulation of a higher molecular mass variant of Bcslp that is not due to an N- or C-terminal maturation defect. Phosphatase treatment experiments suggest that a phosphorylation is not responsible for the observed electrophoretic shift (data not shown), but the shift could be due to another post-translational modification. On the structural model, the F342C mutation is located quite far from the nucleotide-binding site and in the vicinity of the pore region. This pore is formed by homohexameric AAA proteins and is used for the translocation of the different substrate proteins. Mutations in the pore of other AAA proteins affect substrate protein binding and processing without substantially interfering with oligomerisation (for a review, see Ref. 23). We have shown that the F342C mutation does not prevent the formation of Bcslp oligomers and we would like to propose that this mutation alters the conformation of the pore region. We have also isolated several independent extragenic compensatory mutations, suggesting that this residue and probably the region around it is responsible for interactions with other partners or substrate proteins. We have sequenced the genes encoding six subunits of complex III (ISP, Cyt1, Qcr6, Qcr7, Core1, and Core2) and none of them are mutated in the revertants, suggesting that Bcs1p has partners other than complex III. Moreover, it was recently shown that the human Bcslp coprecipitated with the mitochondrial protein LETM1 that is implicated in the human Wolf-Hirschhorn syndrome.15 No mutation in the yeast LETM1 homolog (MDM38) was found in the extragenic revertants. Thus, the extragenic compensatory mutations are not in any obvious candidate genes. Altogether, these results demonstrate that Bcs1p has some unexpected partners or substrates and this could explain why some mutations in the human gene lead to pathologies with no complex III deficiency. In the future, it will be important to develop the study of Bcs1p partners by combining genetic and biochemical approaches.
MATERIALS AND METHODS
Strains, media, and genetic techniques
The CW252 strain (wild type, wt) is isonuclear to W303-1B MATa ade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 and contains an intronless mitochondrial genome.32 GIW252 is identical to CW252 but presents a MATa mating type. Two Δbcs1 strains were used: bcs1::URA3 and bcs1:: kanMX4; the deleted allele bcs1::URA3 strain was constructed by transformation of CW252 with a PCR fragment composed of the URA3 gene flanked by the first and last 20 nucleotides of the BCS1 gene,33 while the deleted allele bcsl::kanMX4 is in the BY4742 nuclear background (MATa his3D1 leu2D0 lys2D0 ura3D0).34 The two strains exhibit the same respiratory-deficient phenotype. The Δrip1 strain, lacking ISP, is isogenic to CW252 but carries a rip1::LEU2 allele. Most media and genetic techniques were as described in Ref. 35. The nonfermentable media contain either 2% glycerol or 3% ethanol and 3% glycerol. The fermentable media contain either 2% glucose or 2% galactose and 0.1% glucose. The maintenance of the mitochondrial genome was regularly tested by crossing the cells with the strain KL14-4A/60, which is devoid of the mitochondrial genome (MATa his1, trp2, rho°), and testing the growth of the diploids on glycerol medium.
Generation of point mutants by random PCR mutagenesis
The BCS1 open reading frame (1370 bp) and 100 bp downstream and upstream of the gene was amplified using the low-fidelity Taq polymerase (Advantage 2, CLONTECH, Palo Alto, CA). The PCR fragments were cloned in the centromeric plasmid pRS416 carrying the URA3 marker36 and the bcsl::kanMX4 cells were transformed with the resulting plasmids. The respiratory phenotypes of the transformants were tested on glycerol/ ethanol medium at 28 and 36 °C. Three mutants, C289Y, F342C, and F432I were integrated at the chromosomal BCS1 locus and a genetic cross with a wild-type strain indicated that the mutations were recessive. The respiratory phenotypes of the chromosomal mutants were identical to those observed with the plasmid-expressed mutants.
UV-induced mutagenesis
For each integrated bcs1 mutant, cells from independent subclones were plated on complete glucose medium, irradiated at 254 nm for 0, 10, and 20 s, and incubated at 28 °C for 3 days. Then the plates were replicated on nonfermentable medium and incubated at 28 °C for the F342C mutant and at 36 °C for the two thermosensitive mutants. Cells growing at 28 or 36 °C were selected and subcloned and total yeast genomic DNA was extracted. The BCS1 gene was PCR-amplified and sequenced to determine if the compensatory mutations were intragenic or extra-genic. This was confirmed by segregation analysis of the respiratory phenotype after crosses with GIW252.

Site-directed mutagenesis
The mutants were generated with a Stratagene Quick-Change™ Site-directed Mutagenesis kit using a pRS416 plasmid carrying the wild-type BCS1 gene and two primers (40mer) carrying the mutation P226A, P226S, or S22ZA. After digestion of the plasmid template by Dpn1, the PCR mix was used to transform Escherichia coli XL Gold. Plasmids extracted from ampicillin-resistant transformants were sequenced to detect the presence of the expected mutation. bcs1::MnMX4 cells were transformed with the different plasmids and grown on glucose and ethanol/glycerol medium at 28 and 36 °C.
Epitope tagging of Bcs1 p and Bcs1-F342Cp
Bcs1p and Bcs1-F342Cp were tagged at the C-terminus and N-terminus with the HA epitope. For the C-terminus, we used the Schizosaccharomyces pombe his5 marker gene (which complements the S. cerevisiae his3 mutation) as described.37 The PCR fragments were used to transform the CW252 and F342C strains to histidine prototrophy. The N-terminus was tagged according to the method of Gauss et al.38 First, a PCR fragment encoding the 6HA tag and the LEU2 gene as auxotrophic marker with two loxP sites on each side was integrated upstream of the BCS1 locus in the wild-type and F342C strains. Then, the LEU+ transformants were retransformed with the plasmid pSH47 carrying the URA3 gene, allowing the expression of the recombinase Cre that recognizes the two loxP sites, and the LEU2 gene was excised. The plasmid pSH47 is finally removed by growing the cells on a medium containing 5-fluoroorotic acid. Correct integration of the tags at the BCS1 locus was confirmed by PCR amplification and sequencing.
Isolation of mitochondria, SDS-PAGE, BN-PAGE, and immunoblotting
Mitochondria were isolated by differential centrifugation after digestion of cell walls with Zymolyase-100T.39 The protein concentration of the final mitochondrial suspension was determined using the Bio-Rad assay (Hercules, CA). Mitochondrial proteins were resolved on denaturating (10% or 12%) SDS-polyacrylamide gels followed by immunoblotting (reinforced nitrocellulose, Schleicher & Schuell, Keene, NH). Protein markers (Precision Plus Protein Standards, Dual Color, Bio-Rad) were used to estimate protein molecular masses. For BN-PAGE, mitochondria were solubilized in digitonin (2%) and the complexes were separated on 5-10% polyacrylamide gradient gels as described in Ref. 40 and modified by Lemaire and Dujardin.41 Protein markers (High Molecular Weight Calibration kit for native electrophoresis, Amersham Biosciences) were used to estimate molecular weights. Polyclonal antibodies against Cyt1p were raised against a fusion proA-Cytlp expressed in E. coli. Monoclonal anti-Hsp60p was from Molecular Probes (Eugene, OR), the anti-HA was from Santa Cruz Biotechnology, and the polyclonal anti-ISP was a gift from C. Godinot (Lyon, France). Bound antibodies were detected by horseradish-peroxidase-conjugated secondary antibodies (Promega, Madison, WI). Proteins were visualized using a chemiluminescent substrate (Pierce Chemical, Rockford, IL).
Production of a Bcsl p-specific antibody
A 1765-bp PCR fragment carrying the BCS1 gene was cloned in the pGemTeasy vector (Promega). Digestion with SalI and NotI led to a 1354-bp fragment encoding of the soluble part of Bcs1p (372 aa). This fragment was cloned in the digested pET24b vector (Novagen) downstream of the T7 promoter and lac operator. This plasmid was used to transform E. coli BL21 (DE3, Novagen). Addition of IPTG to cell cultures reaching an OD of 0.6 allowed the overproduction of the 41-kDa fragment of Bcs1p that was recovered from the gel and injected to rabbits.
Measurement of iron content
Iron was measured according to.42 Total cell extracts or purified mitochondria (100 or 300 µg) were suspended in 10 mM Mes and 0.5% SDS (pH 5.5) and mixed with a Vortex shaker for 10 min at room temperature. Then bathophenanthroline (BPS) was added to a final concentration of 5 mM. Finally, saturated dithionite was added to reduce free iron. The complex absorption of the BPS/Fe2+ was measured at 535 nm. The concentration of Fe2+ was determined by comparison with a standard curve established with FeSO4 solubilized in 0.1 M HCl.
Structural model of the AAA domain of the yeast and human Bcs1p
Structural homologs of AAA domains of Bcs1p were found using the BLAST software at the National Center for Biotechnology Information (NCBI)† and Protein Data Bank was used as the reference database. Seven structural homologs were chosen for modeling: 1E32, 1IXZ, 1IY1, 1LV7, 1S3S, 2CE7, and 2QZ4. Alignments between the seven structures were performed with the STRAP Software43 generating a linear alignment between the templates, which were further used as templates for aligning yeast or human Bcs1p. During the alignment, careful attention to the position of the secondary-structure elements was taken when gaps had to be introduced. Modeling was performed with the Modeller 9v3 software44 on either the yeast or the human form independently. The models generated were checked with Modeller 9v3 (DOPE and GA341 energy outputs) and Procheck 3.5.445 for stereochemistry, angle, and bond accuracy. The two final models were deposited in the Protein Model Database‡ with the following identification numbers: PM0075341 and PM0075342 for the human and yeast AAA domain of Bcs1 proteins, respectively. For a complete description of the modeling steps and procedures, please refer to the Supplementary Material.
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